on IKONISYS (EPA:ALIKO)
Ikonisys and Ulisse Biomed enter into a strategic partnership for cancer diagnosis
Paris, France, and Trieste, Italy – June 11, 2024 - Ikonisys SA and Ulisse Biomed announce a strategic collaboration to improve their technical capabilities in the field of cancer diagnostics.
Ikonisys, specialized in the early and precise detection of cancers, and Ulisse Biomed, a health care biotechnology company, are combining their expertise. This partnership aims to integrate molecular biology technologies from UBM and fluorescence in situ hybridization (FISH) from Ikonisys.
The two companies plan to cross-sell and jointly market their products. An in-depth technical study will be carried out to optimize technologies and guarantee product quality.
The cooperation will begin with the joint installation of instruments in the Hospitalex laboratory in Florence. A demo day to introduce the technologies to customers is planned for fall 2024.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IKONISYS news